Abstract:Glioblastoma, IDH-wildtype remains a molecularly heterogeneous disease that is refractory to current therapies. To investigate how longitudinal epigenomic evolution of glioblastoma drives tumor progression and treatment resistance, we performed comprehensive histopathologic assessment, targeted genomic sequencing, and genome-wide DNA methylation profiling of paired initial and recurrent IDH-wildtype glioblastoma samples from 98 patients, as well as a separate longitudinal cohort of IDH-mutant astrocytomas for comparison. Primary treatment-naïve IDH-wildtype glioblastomas had more globally hypomethylated genomes compared to primary IDH-mutant astrocytomas. At time of recurrence, IDH-mutant astrocytomas uniformly became more hypomethylated similar to the global methylation levels in IDH-wildtype glioblastomas. In contrast, recurrent IDH-wildtype glioblastomas were heterogeneous with subsets becoming more globally hypermethylated (27%), hypomethylated (22%), or remaining stable (51%). Accordingly, a substantial proportion (52%) of recurrent glioblastomas underwent methylation class switching compared to their matched primary tumor, with a predominance of the RTK2 epigenetic subtype at initial surgery and the Mesenchymal epigenetic subtype at recurrence. Among approximately 850,000 interrogated CpG sites, we identified only 110 and 153 sites that consistently became more hypermethylated or hypomethylated between initial and recurrent IDH-wildtype glioblastomas, which regulate genes involved in neuronal morphogenesis, oligodendrocyte differentiation, and myelination. In contrast, we identified 260 and 18,527 CpG sites that consistently became more hypermethylated or hypomethylated between initial and recurrent IDH-mutant astrocytomas, which regulate genes involved in neuronal stem-like differentiation, cell cycle control, and other biologic processes. Finally, we developed a DNA methylation evolution signature incorporating change in mean beta-methylation values from initial to recurrent tumor specimens across 347 critical CpG sites that significantly correlated with clinical outcomes for patients with IDH-wildtype glioblastoma. In summary, IDH-wildtype glioblastomas demonstrate heterogeneous epigenomic evolution patterns distinct from IDH-mutant astrocytomas. These changes in epigenetic patterns may identify unique subgroups of glioblastoma with differential treatment response and inform future therapeutic studies targeting differentially methylated gene programs.

Epco-15. Intra-Tumoral Heterogeneity Of Dna Methylation Profiling And Cellular Composition In Glioblastoma

Spatial progression and molecular heterogeneity of IDH-mutant glioblastoma determined by DNA methylation-based mapping

DNA methylation heterogeneity attributable to a complex tumor immune microenvironment prompts prognostic risk in glioma

Epco-34. Deciphering The Longitudinal Trajectories Of Glioblastoma By Integrative Single-Cell Genomics

Temporal change of DNA methylation subclasses between matched newly diagnosed and recurrent glioblastoma

Epco-19. Multiomic Profiling Of Epigenetic Heterogeneity In Glioblastoma At Single-Cell Resolution Using Multiomic Single-Cell Cut&Tag

Epco-48. Resolving Intratumoral Transcriptional Heterogeneity Across The Core-Edge Spatial Axis In Glioblastoma

Analysis of gliomas DNA methylation: Assessment of pre-analytical variables

Epco-18. Deciphering Spatial Diversity Of Glioblastoma Genetic Architecture

Epco-03. Metabolic Insight Into Glioma Heterogeneity: Mapping Whole Exome Sequencing Toin Vivo Imaging With Stereotactic Localization And Deep Learning

Mean global DNA methylation serves as independent prognostic marker in IDH-wildtype glioblastoma

Tumor Heterogeneity and Molecular Characteristics of Glioblastoma Revealed by Single-Cell RNA-Seq Data Analysis

DNA methylation in glioblastoma: impact on gene expression and clinical outcome

Highly Multiplexed Spatially Resolved Proteomic and Transcriptional Profiling of the Glioblastoma Microenvironment Using Archived Formalin-Fixed Paraffin-Embedded Specimens

Biom-67. Differential Dna Methylation Patterns In The Csf Of Patients With Diffuse Gliomas

Path-29. Longitudinal Epigenomic Evolution Of Idh-Wildtype Glioblastoma

Biom-66. Genome-Wide Dna Methylation Patterns In Peripheral Blood Of Patients With Glioblastoma Enrolled On The Phase Ii Vertu Trial

Glioblastoma epigenomics discloses a complex biology and potential therapeutic targets

Detection of glioma and prognostic subtypes by non-invasive circulating cell-free DNA methylation markers

Single-cell epigenetic analysis reveals principles of chromatin states in H3.3-K27M gliomas

Abstract 3497: Glioma Immune Microenvironment Composition Calculator (GIMiCC): A method of estimating the proportions of eighteen key cell types from human brain tissue assayed using Illumina DNA methylation microarray technology